Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial

What Was Tested

This randomized controlled trial paper looks at Liraglutide.

Polycystic ovary syndrome (PCOS) encompasses an ovarian and a metabolic dysfunction.

Glucagon-like peptide-1 (GLP-1) analogues facilitate weight loss and ameliorate metabolic dysfunction in overweight women with PCOS, but their effect on ovarian dysfunction is scarcely reported.

Who Took Part

The study group was 72 women.

By PubMed's age tags, the people studied were adults, women only.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Liraglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the women and researchers unaware of who received Liraglutide.

A placebo (an inactive look-alike) gave the Liraglutide group a baseline to be compared against.

At baseline and 26-week follow-up, bleeding pattern, levels of AMH, sex hormones and gonadotrophins were assessed and ovarian morphology evaluated.

What Was Measured

Topics PubMed links to this paper include Hypoglycemic Agents, Liraglutide, Polycystic Ovary Syndrome and Testosterone.

Author keywords: Androgens, Anti-Müllerian hormone, Menstruation and Ovarian morphology.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Liraglutide in 72 women.

The publication is from 2017 (Reproductive biomedicine online), a journal based in Netherlands.

More context: the Liraglutide compound page, all human trials.